Shares of Merck KGaA (FRA:MRK) have been given a consensus rating of “Hold” by the twenty-one brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, fourteen have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is €100.00 ($116.28).
Several brokerages recently commented on MRK. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the company a “buy” rating in a research report on Friday, March 8th. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the company a “buy” rating in a research report on Wednesday, February 6th. Warburg Research set a €103.00 ($119.77) price target on Merck KGaA and gave the company a “neutral” rating in a research report on Wednesday. Barclays set a €78.00 ($90.70) price target on Merck KGaA and gave the company a “sell” rating in a research report on Tuesday, January 15th. Finally, Independent Research set a €100.00 ($116.28) price target on Merck KGaA and gave the company a “neutral” rating in a research report on Friday, March 1st.
Shares of FRA:MRK traded down €1.57 ($1.83) during mid-day trading on Thursday, reaching €98.68 ($114.74). 498,508 shares of the stock were exchanged. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Further Reading: Is it better to buy a fund with a higher or lower NAV?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.